KSQ Therapeutics Inc

We recently participated in a panel at the Immuno-Oncology 360 Summit in Boston. Before the meeting, the organizers interviewed our CMO, Anna Truppel-Hartmann, about her work at KSQ and what drives her personally. Read more about it here: bit.ly/3Oauxgs

At the 7th Annual TIL Therapies Summit, our Chief Scientific Officer, Micah Benson, will present an update on our pipeline and take part in a fireside chat on the current state of TIL Tx in the clinic. We hope to see you there! bit.ly/3JFxPGx

We’re presenting 3 posters at the #SITC2025 Annual Meeting: 1) preclinical KSQ-004EX data; 2) trial in progress of our KSQ-004EX Phase 1/2 clinical study; and 3) preclinical data showing how inactivation of SOCS1 and Regnase-1 enhances CAR-T function against solid tumors.

Sunshine, good vibes, and even better company! KSQ’s summer outing brought the team together for a day of relaxation, fun, and laughter outside the office. It’s moments like these that remind us why we love what we do, and who we do it with. #KSQSummerOuting2025 #WorkHardPlayHard

At KSQ, we aim to nurture growth in every way possible. This summer, we worked together to create a garden bed filled with flowers and herbs, demonstrating our commitment to building strong relationships, enhancing collaboration, and giving back to the community.📷

Today at the Annual Tumor Models Summit, Katarina Halpin-Veszeleiova will present on improving cell therapy development with mouse models, including selection/optimization considerations, data benchmarking, and uncovering mechanisms of action.  We hope to see you there!

With its best-in-class edits, KSQ-004EX has the potential to deliver durable and transformative outcomes in a variety of advanced solid tumor indications.

Next week at #ASCO25 we will present a Trial In Progress poster of our Phase 1/2 clinical study of KSQ-004EX, a novel CRISPR-engineered eTIL® therapy in which SOCS1 and Regnase-1 are inactivated.

Today at #AACR25, David Monteiro will present a poster reporting the impact of SOCS1 and Regnase-1 inactivation on tumor-specific eTIL® in our clinical-stage KSQ-001EX and KSQ-004EX therapies. We look forward to seeing our friends and colleagues at the meeting!

Our unique approach to developing TILs for solid tumors via CRISPR-Cas9 engineering was featured in GEN recently. It’s a great look at the future potential of TIL therapy. Thanks to @GENBio and @TiffanyYesavage. bit.ly/3XWNwx0

KSQ’s CRISPRomics® platform identified SOCS1 and Regnase-1 as key genes inhibiting the ability of TIL to eradicate solid tumors in preclinical models. CEO, @Qasim Rizvi comments on the potential of KSQ-004EX. bit.ly/4jiFVkC

KSQ-004EX consists of eTIL in which the SOCS1 and Regnase-1 genes are inactivated by CRISPR/Cas9 gene editing, giving it the potential to be a best-in-class treatment for a variety of solid tumor indications.

Today we announced the first patient was dosed in the Phase 1/2 clinical study of KSQ-004EX, a novel CRISPR-engineered (eTIL®) therapy. Learn more: bit.ly/4jiFVkC

Next week our team will present at the Cell Therapy Potency Assay Summit in Boston. They will explore best practices for simplifying potency assays and reviewing quality control-friendly technologies to streamline workflow. We hope to see you there!

We’re proud to announce Kristen Hege, M.D., will join our BoD. Dr. Hege has more than 20 years of leadership experience in oncology & cell therapy R&D. She has brought multiple programs to clinical proof of concept, and a cell therapy to FDA approval. bit.ly/4ikhjYN

They also discuss how KSQ and other companies can leverage data scientists to drive innovation and enhance therapeutic development. youtu.be/Nr7YJk8qBKA?si…

Listen to CorrDyn’s Data in Biotech podcast this week to hear our VP of Data Sciences, Dipen Sangurdekar, speak with host Ross Katz about the importance of data science in biotechnology today.

These outstanding individuals go above and beyond to meaningfully impact our organization. Thank you for your continued dedication and commitment to improving our workplace daily. Here’s to a new year filled with continued success and excellence!

Each year, we give colleagues the chance to nominate individuals who have truly embodied KSQ’s core values. We are thrilled to recognize our 2024 awardees: Collaboration: Ashish Yeri and Conor Calnan Authenticity: Ben Askin Resilience: Pam Sullivan Excellence: Dominick Matos

Next Wednesday, join KSQ’s Head of Cell Therapy, Karrie Wong, at Advanced Therapies Week. She’ll discuss the promise of TIL therapy with Amy Lamperti from WuXi Advanced Therapies and Chris White, TIL therapy recipient and author of Killing Cancer With TILs.